Skip to main content
OpenTrials
Completed

NCT Number: NCT02445560

The Effects of a High Protein Diet on Microbiota, Gastrointestinal Function and Wellness in Older Women

The purpose of the proposed study is to determine the effects of consuming a high protein diet on fecal microbial communities, gastrointestinal function and symptoms, and general wellness in older adults.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

65 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

UF Food Science and Human Nutrition Department, Gainesville, Florida, United States

Loading trial locations.

About this study

Older women will be randomized to a 18-week crossover study design. During each treatment period participants will be provided with a weight maintenance diet providing approximately 2 g/kg/day of protein.

Following a two-week baseline and in random order will have the following diets assigned:

The participants will be provided with a weight maintenance, high protein diet for two weeks, then for two-weeks will resume their normal diet;

The participants will come back into clinic and for the next two weeks to receive a high protein diet with a multi-strain probiotic for two weeks, then for two-weeks will resume their normal diet;

The participants will come back into clinic and for the next two weeks will receive a high protein diet with a prebiotic, then for two-weeks will resume their normal diet;

The participants will come back into clinic and for the next two weeks will receive a high protein diet with the synbiotic combination. then for two-weeks will resume their normal diet

Participants and researchers will be blinded for each treatment period (participants will receive a probiotic or placebo capsule, and a prebiotic or placebo sachet).

The following will be performed during the clinic visits: Questionnaires will assess quality of life (QoL), wellness, gastrointestinal symptoms, bowel movement frequency, and compliance. Hand-grip strength will be measured. Blood and urine samples will be collected at baseline and at weeks 2, 6,10 and 14. Stool samples will be collected at baseline and at weeks 2, 4, 6, 8,10, 12, 14 and 16.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

To participate in the study you must

  • be a woman 65 years of age or older
  • be willing to complete daily and weekly questionnaires
  • be willing to wear a SenseWear Pro Armband (BodyMedia, Inc.) to monitor energy expenditure and establish dietary energy needs
  • be willing to provide blood samples, stool samples, and urine samples throughout the course of the study
  • be willing to discontinue prebiotics, probiotics and/or any fiber supplements for the duration of the study
  • be willing to consume the provided diet for the designated 8 weeks of the study
  • are willing to report and maintain their usual alcohol intake throughout the study
  • are able to take foods, study fiber, probiotic, and placebo without the aid of another person
  • able to attend all scheduled study appointments for the duration of the study
  • have a usual protein intake consistent with United States' population as assessed by dietary analysis
  • have a usual fiber intake consistent with United States' population as assessed by dietary analysis
  • be willing to provide a social security number to receive study payment.

Exclusion criteria

To participate in the study you must NOT

  • have a physician-diagnosed gastrointestinal disease or condition (such as ulcerative colitis, Crohn's disease, gastroparesis, peptic ulcer disease, cancer, celiac disease, short bowel disease, ileostomy)
  • have had or are currently being treated for any known illnesses or conditions that may impact perceived health such as HIV/AIDS, immune modulating diseases (autoimmune, hepatitis, cancer, etc.), diabetes or chronic kidney disease
  • be a vegetarian
  • have any known food allergies or dietary restrictions
  • be currently taking medication for constipation or diarrhea
  • have taken antibiotics within the past 2 months
  • be a current smoker
  • be planning on loosing/gaining weight during the next 6 months
  • typically consume no more than one alcoholic beverage per day
  • have a BMI greater than 30

Treatment and study plan

Probiotic capsule and Fiber Sachet

Dietary Supplement

A probiotic capsule and fiber sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The fiber sachet consists of 5 g of chicory root fiber.

During the treatment period, in addition to consuming the probiotic capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.

Probiotic capsule and Placebo sachet

Dietary Supplement

A probiotic capsule and placebo sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The placebo sachet consists of 5 g of maltodextrin.

During the treatment period, in addition to consuming the probiotic capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.

Placebo capsule and Fiber Sachet

Dietary Supplement

A placebo capsule and fiber sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of chicory root fiber.

During the treatment period, in addition to consuming the placebo capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.

Placebo capsule and Placebo sachet

Dietary Supplement

A placebo capsule and placebo sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of maltodextrin.

During the treatment period, in addition to consuming the placebo capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.

Primary outcomes

  1. Microbiota Studies (recovery)

    Time frame: Change from Baseline at Week 2,4,6,8,10,12,14,16

    Change in the concentrations of the probiotic strains in the stools will be measured with strain specific deoxyribonucleic acid (DNA) (or antibodies) in fecal samples (e.g. quantitative polymerase chain reaction (qPCR), flow cytometry).

  2. Microbiota Studies (overall composition)

    Time frame: Change from Baseline at Week 2,4,6,8,10,12,14,16

    Effects of the probiotic interventions on overall microbiota composition (e.g. 454 16S rRNA (ribosomal ribonucleic acid) sequencing) will also be measured.

Secondary outcomes

  1. Digestive Health (Gastrointestinal Symptom Rating Scale )

    Time frame: Change from Baseline at Week 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18

    Measured by gastrointestinal symptoms (gas, bloating, diarrhea, etc.) assessed using the weekly Gastrointestinal Symptom Rating Scale (GSRS).

  2. Digestive Health (Bristol Stool Scale)

    Time frame: Change from Baseline at Week 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18

    Measured by gastrointestinal symptoms (gas, bloating, diarrhea, etc.) assessed using a daily questionnaire. The daily questionnaire will include questions regarding symptoms and the Bristol Stool Scale (stool form and transit).

  3. Blood Analysis (metabolic)

    Time frame: Change from Baseline at Weeks 2,6,10,14

    Measured by comprehensive Metabolic Panel

  4. Blood Analysis (lipids)

    Time frame: Change from Baseline at Weeks 2,6,10,14

    Measured by Lipid Panel

  5. Blood Analysis (inflammation)

    Time frame: Change from Baseline at Weeks 2,6,10,14

    Measured by Inflammatory markers

  6. Blood Analysis (blood count)

    Time frame: Change from Baseline at Weeks 2,6,10,14

    Measured by Complete Blood Count (CBC)

  7. Blood Analysis (signalling)

    Time frame: Change from Baseline at Weeks 2,6,10,14

    Measured by (mammalian target of rapamycin) mTOR

  8. Blood Analysis (regulation)

    Time frame: Change from Baseline at Weeks 2,6,10,14

    Measured by insulin-like growth factor 1 (IGF-1)

  9. Blood Analysis (proteolysis)

    Time frame: Change from Baseline at Weeks 2,6,10,14

    Measured by total p-cresol

  10. General Wellness

    Time frame: Day 1 through 126

    Individual reporting of antibiotic usage, visits to a physician, etc.

  11. Proteolytic Activity

    Time frame: Change from Baseline at Weeks 2,6,10,14

    Measured by urinary p-cresol, indoxyl sulfate and urine urea nitrogen (UUN)

  12. Measures of Quality of Life (QoL)

    Time frame: Change from Baseline at Weeks 2,6,10,14

    QoL questionnaire (domains such as physical functioning, general health, bodily pain, vitality, social functioning), questionnaire to assess frailty, and hand grip strength

  13. Measures of Well-being (frailty)

    Time frame: Change from Baseline at Weeks 2,6,10,14

    Questionnaire to assess frailty

  14. Measures of Well-being (hand grip)

    Time frame: Change from Baseline at Weeks 2,6,10,14

    Hand grip strength will be measured

  15. Acceptability of the Diet

    Time frame: Day 1 through 126

    Acceptability will be measured using the daily questionnaire and participant compliance recordings/logs of any unconsumed foods during treatment periods

Sponsors and collaborators

Lead sponsor

University of Florida

Other

Collaborators

  • Lallemand Health Solutions

Registry information

Official study title

The Effects of a High Protein Diet on Microbiota, Gastrointestinal Function, Wellness and the Potential Mitigating Effects of a Multi-strain Probiotic, Prebiotic, and Synbiotic: a Randomized, Double-blinded Crossover Study in Older Women.

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
May 15, 2015
Registry last updated
Mar 29, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.